ARDX - Ardelyx Inc Stock Price, Fair Value and News

7.84USD-0.18 (-2.24%)Delayed as of 14 May 2024, 11:01 am ET

Market Summary

USD7.84-0.18

Delayedas of 14 May 2024, 11:01 am

-2.24%

ARDX Alerts

4 major insider sales recently.

Big jump in Revenue (Y/Y)
Losses in recent quarter

ARDX Stock Price

View Fullscreen

ARDX RSI Chart

ARDX Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-28.51

Price/Sales (Trailing)

11.79

EV/EBITDA

-32.2

Price/Free Cashflow

-23.13

ARDX Price/Sales (Trailing)

ARDX Profitability

Operating Margin

96.50%

EBT Margin

-40.95%

Return on Equity

-43.62%

Return on Assets

-19.22%

Free Cashflow Yield

-4.32%

ARDX Fundamentals

ARDX Revenue

Revenue (TTM)

159.1M

Rev. Growth (Yr)

304.81%

Rev. Growth (Qtr)

33.93%

ARDX Earnings

Earnings (TTM)

-65.8M

Earnings Growth (Yr)

0.95%

Earnings Growth (Qtr)

7.93%

Breaking Down ARDX Revenue

52 Week Range

3.198.11

(Low)(High)

Last 7 days

-12.3%

Last 30 days

13.6%

Last 90 days

-9.5%

Trailing 12 Months

87.0%

How does ARDX drawdown profile look like?

ARDX Financial Health

Current Ratio

4.53

ARDX Investor Care

Shares Dilution (1Y)

9.10%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	159.1M	0	0	0
2023	63.1M	82.9M	134.3M	124.5M
2022	4.0M	5.2M	9.0M	52.2M
2021	12.9M	12.4M	10.9M	10.1M
2020	6.6M	8.3M	8.0M	7.6M
2019	0	0	3.3M	5.5M
2018	44.3M	44.4M	44.5M	2.6M
2017	0	0	0	60.1M
2015	29.0M	38.0M	30.4M	24.0M
2014	30.9M	32.8M	33.8M	31.6M
2013	11.3M	17.2M	23.0M	28.9M
2012	0	0	0	5.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ardelyx Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	felsch robert ora	acquired	176,445	1.48147	119,101	see remarks
May 06, 2024	felsch robert ora	sold	-1,831,500	8.80581	-207,988	see remarks
May 06, 2024	grammer elizabeth a	acquired	410,787	1.86775	219,937	see remarks
May 06, 2024	grammer elizabeth a	sold	-2,522,220	8.87573	-284,170	see remarks
May 03, 2024	williams laura a	acquired	29,700	0.99	30,000	chief medical officer
May 03, 2024	grammer elizabeth a	sold	-405,000	9.00	-45,000	see remarks
May 03, 2024	williams laura a	sold	-333,574	8.35	-39,949	chief medical officer
Apr 29, 2024	raab michael	sold	-192,057	6.4019	-30,000	president & ceo
Apr 29, 2024	raab michael	acquired	29,700	0.99	30,000	president & ceo

Which funds bought or sold ARDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Rubric Capital Management LP	reduced	-54.73	-11,618,000	13,261,100	0.39%
May 10, 2024	BlackRock Inc.	added	1.91	20,789,500	124,801,000	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	1,500	1,328	1,402	-%
May 10, 2024	Sargent Investment Group, LLC	sold off	-100	-122,878	-	-%
May 10, 2024	CREDIT SUISSE AG/	added	1.85	328,936	1,980,220	-%
May 10, 2024	Covestor Ltd	reduced	-73.51	-39,000	17,000	0.01%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	9.7	192,160	851,027	-%
May 10, 2024	LPL Financial LLC	added	24.25	298,290	942,693	-%
May 10, 2024	CITIGROUP INC	added	69.82	3,442,930	6,887,500	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-31.11	-414,749	1,781,640	-%

Are Funds Buying or Selling ARDX?

Are funds buying ARDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARDX

No. of Funds

Unveiling Ardelyx Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	janus henderson group plc	10.6%	24,658,820	SC 13G/A
Feb 13, 2024	vanguard group inc	5.61%	13,026,046	SC 13G
Jan 31, 2024	millennium management llc	0.0%	6,286	SC 13G/A
Jan 30, 2024	state street corp	7.37%	17,102,598	SC 13G/A
Jan 26, 2024	blackrock inc.	7.2%	16,776,055	SC 13G
Jul 10, 2023	state street corp	10.46%	22,437,564	SC 13G
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A
Feb 07, 2023	millennium management llc	5.1%	10,162,045	SC 13G
Jan 27, 2023	millennium management llc	5.4%	10,634,329	SC 13G/A
Jan 10, 2023	janus henderson group plc	10.5%	19,774,333	SC 13G

Recent SEC filings of Ardelyx Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	144	Notice of Insider Sale Intent
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 01, 2024	4	Insider Trading

Peers (Alternatives to Ardelyx Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Ardelyx Inc News

Latest updates

Ardelyx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4	2018Q3
Revenue	33.9%	46,023,000	34,363,000	56,391,000	22,333,000	11,369,000	44,178,000	4,986,000	2,526,000	468,000	1,029,000	1,173,000	1,313,000	6,582,000	1,809,000	2,713,000	1,836,000	1,213,000	2,250,000	3,013,000	85,000	172,000
Cost Of Revenue	-	-	-	-	-	1,537,000	3,162,000	732,000	138,000	85,000	-	-	-	1,000,000	4,000	-	141,000	-	-	600,000	-	2,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,250,000	2,413,000	85,000	170,000
Costs and Expenses	12.5%	63,573,000	56,503,500	41,301,000	35,468,000	37,433,000	28,830,500	26,134,000	28,603,000	28,275,000	35,302,000	43,409,000	46,145,000	38,587,000	29,452,000	19,874,000	26,043,000	22,982,000	21,098,000	25,102,000	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22,982,000	21,098,000	24,502,000	27,461,000	23,902,000
S&GA Expenses	11.0%	52,994,000	47,748,000	32,664,000	27,186,000	26,803,000	19,731,000	18,667,000	18,862,000	19,339,000	15,334,000	19,714,000	20,124,000	17,131,000	11,343,000	7,634,000	7,038,000	7,138,000	6,857,000	6,922,000	5,425,000	5,961,000
R&D Expenses	11.1%	10,579,000	9,524,000	8,637,000	8,282,000	9,093,000	9,142,000	7,467,000	9,741,000	8,851,000	20,968,000	23,695,000	26,021,000	20,456,000	18,105,000	12,240,000	18,864,000	15,844,000	14,241,000	17,580,000	22,036,000	17,941,000
EBITDA Margin	24.6%	-0.36	-0.48	-0.16	-0.62	-0.98	-1.20	-12.12	-24.70	-36.68	-14.94	-13.10	-9.51	-	-	-	-	-	-	-	-	-
Interest Expenses	35.4%	2,356,000	1,740,000	1,107,000	1,075,000	1,028,000	991,000	886,000	777,000	746,000	984,000	1,216,000	1,202,000	1,100,000	1,314,000	1,202,000	1,226,000	1,357,000	1,398,000	1,443,000	-	1,404,000
Income Taxes	-63.7%	121,000	333,000	200,000	-	14,000	-	-	6,000	2,000	-	1,000	2,000	1,000	2,000	-	-	-	-	301,000	-2,000	-
Earnings Before Taxes	7.3%	-26,397,000	-28,469,000	6,829,000	-17,121,000	-26,759,000	10,695,000	-22,893,000	-26,932,000	-28,069,000	-36,234,000	-43,586,000	-45,187,000	-33,154,000	-28,874,000	-18,108,000	-24,956,000	-22,373,000	-19,790,000	-23,238,000	-27,864,000	-24,126,000
EBT Margin	22.2%	-0.41	-0.53	-0.20	-0.68	-1.04	-1.29	-12.67	-25.95	-38.43	-15.66	-13.86	-10.09	-	-	-	-	-	-	-	-	-
Net Income	7.9%	-26,518,000	-28,802,000	6,629,000	-17,121,000	-26,773,000	10,695,000	-22,893,000	-26,938,000	-28,071,000	-36,234,000	-43,587,000	-45,189,000	-33,155,000	-28,876,000	-18,108,000	-24,956,000	-22,373,000	-19,790,000	-23,539,000	-27,862,000	-24,126,000
Net Income Margin	22.1%	-0.41	-0.53	-0.20	-0.68	-1.05	-1.29	-12.67	-25.95	-38.43	-15.66	-13.86	-10.09	-	-	-	-	-	-	-	-	-
Free Cashflow	-309.5%	-35,872,000	-8,761,000	-21,661,000	-14,830,000	-44,809,000	14,229,000	-25,427,000	-31,281,000	-27,620,000	-39,374,000	-35,034,000	-35,015,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	15.1%	342	298	289	211	217	190	145	132	129	150	171	205	210	202	199	217	235	260	119	138	166
Current Assets	4.8%	258	246	241	162	167	154	120	114	114	134	153	186	205	195	194	212	229	252	111	127	154
Cash Equivalents	68.4%	36.00	21.00	34.00	30.00	92.00	96.00	62.00	53.00	47.00	72.00	75.00	87.00	84.00	91.00	91.00	100	106	181	93.00	90.00	92.00
Inventory	59.4%	79.00	49.00	-	-	-	-	-	5.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	1.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00
Liabilities	46.4%	191	131	98.00	88.00	92.00	92.00	78.00	79.00	65.00	67.00	89.00	87.00	79.00	75.00	67.00	71.00	68.00	73.00	70.00	69.00	74.00
Current Liabilities	12.9%	57.00	50.00	44.00	62.00	63.00	66.00	52.00	49.00	48.00	53.00	69.00	58.00	42.00	28.00	17.00	34.00	23.00	22.00	18.00	16.00	21.00
LT Debt, Current	-	-	-	-	-	-	-	27.00	26.00	26.00	32.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-9.5%	151	167	191	123	125	98.00	67.00	53.00	64.00	83.00	81.00	118	131	126	131	146	168	187	49.00	69.00	92.00
Retained Earnings	-3.1%	-872	-846	-817	-824	-806	-780	-790	-767	-741	-712	-676	-633	-587	-554	-525	-507	-482	-460	-440	-417	-391
Additional Paid-In Capital	1.1%	1,024	1,013	1,009	947	932	879	858	821	805	796	758	751	719	681	657	654	651	647	490	486	483
Shares Outstanding	0.6%	234	232	232	218	214	199	147	146	131	104	100	100	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	725	-	-	-	89.00	-	-	-	769	-	-	-	612	-	-	-	126	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-309.7%	-35,722	-8,718	-21,467	-14,737	-44,795	14,284	-25,427	-31,281	-27,620	-39,469	-34,589	-34,276	-44,217	-17,590	-19,877	-19,022	-24,946	-11,137	-20,614	-27,820	-16,913
Share Based Compensation	93.8%	7,616	3,930	3,489	3,199	2,912	1,926	1,848	3,254	3,722	3,471	2,262	3,219	3,087	2,434	2,527	2,674	2,948	2,212	3,879	1,923	1,922
Cashflow From Investing	91.3%	-2,572	-29,567	-32,697	-59,207	-9,777	1,441	-832	15,474	2,332	22,096	18,133	8,234	2,485	-3,570	9,594	13,417	-50,883	-55,461	23,448	25,405	29,981
Cashflow From Financing	103.8%	52,971	25,988	57,873	11,515	50,919	18,787	34,479	22,138	-63.00	14,513	4,999	28,717	34,770	21,183	798	204	591	155,058	213	5.00	200

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARDX Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 46,023	$ 11,369
Cost of goods sold:
Total cost of goods sold	7,128	1,537
Operating expenses:
Research and development	10,579	9,093
Selling, general and administrative	52,994	26,803
Total operating expenses	63,573	35,896
Loss from operations	(24,678)	(26,064)
Interest expense	(2,356)	(1,028)
Non-cash interest expense related to the sale of future royalties	(1,702)	(969)
Other income, net	2,339	1,302
Loss before provision for income taxes	(26,397)	(26,759)
Provision for income taxes	121	14
Net loss	$ (26,518)	$ (26,773)
Net loss per share of common stock - basic (in dollars per share)	$ (0.11)	$ (0.13)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.11)	$ (0.13)
Shares used in computing net loss per share - basic (in shares)	233,065,960	207,023,127
Shares used in computing net loss per share - diluted (in shares)	233,065,960	207,023,127
Comprehensive loss:
Net loss	$ (26,518)	$ (26,773)
Unrealized (losses) gains on available-for-sale securities	(244)	34
Comprehensive loss	(26,762)	(26,739)
Product sales, net
Revenues:
Total revenues	43,512	11,355
Cost of goods sold:
Total cost of goods sold	1,013	372
Product supply revenue
Revenues:
Total revenues	2,126	2
Licensing revenue
Revenues:
Total revenues	17	12
Non-cash royalty revenue related to the sale of future royalties
Revenues:
Total revenues	368	0
Other cost of revenue
Cost of goods sold:
Total cost of goods sold	$ 6,115	$ 1,165

ARDX Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 36,147	$ 21,470
Short-term investments	166,431	162,829
Accounts receivable	28,162	22,031
Inventory	9,813	12,448
Prepaid commercial manufacturing	5,519	18,925
Prepaid expenses and other current assets	11,867	8,408
Total current assets	257,939	246,111
Inventory, non-current	69,045	37,039
Prepaid commercial manufacturing, non-current	4,235	4,235
Right-of-use assets	4,641	5,589
Property and equipment, net	1,019	1,009
Other assets	5,503	3,596
Total assets	342,382	297,579
Current liabilities:
Accounts payable	17,277	11,138
Accrued compensation and benefits	6,727	12,597
Current portion of operating lease liability	4,314	4,435
Deferred revenue	6,586	7,182
Accrued expenses and other current liabilities	21,991	15,041
Total current liabilities	56,895	50,393
Operating lease liability, net of current portion	778	1,725
Long-term debt, net of current portion	99,834	49,822
Deferred revenue, non-current	12,103	8,644
Deferred royalty obligation related to the sale of future royalties	21,881	20,179
Total liabilities	191,491	130,763
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 233,959,744 and 232,453,190 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	23	23
Additional paid-in capital	1,023,610	1,012,773
Accumulated deficit	(872,722)	(846,204)
Accumulated other comprehensive (loss) income	(20)	224
Total stockholders’ equity	150,891	166,816
Total liabilities and stockholders’ equity	$ 342,382	$ 297,579

About Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Michael G. Raab
WEBSITE	ardelyx.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Ardelyx Inc Frequently Asked Questions

What is the ticker symbol for Ardelyx Inc? What does ARDX stand for in stocks?

ARDX is the stock ticker symbol of Ardelyx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ardelyx Inc (ARDX)?

As of Mon May 13 2024, market cap of Ardelyx Inc is 1.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARDX stock?

You can check ARDX's fair value in chart for subscribers.

What is the fair value of ARDX stock?

You can check ARDX's fair value in chart for subscribers. The fair value of Ardelyx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ardelyx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ardelyx Inc a good stock to buy?

The fair value guage provides a quick view whether ARDX is over valued or under valued. Whether Ardelyx Inc is cheap or expensive depends on the assumptions which impact Ardelyx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDX.

What is Ardelyx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ARDX's PE ratio (Price to Earnings) is -28.51 and Price to Sales (PS) ratio is 11.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDX PE ratio will change depending on the future growth rate expectations of investors.